依那西普（恩利）——最新情况
Etanercept (Enbrel) -- an update.
作者信息
Goffe B
机构信息
Department of Dermatology, University of Washington Medical School, Seattle, WA, USA.
出版信息
Skin Therapy Lett. 2004;9(10):1-4, 9.
PMID:15657632
Abstract
Etanercept is a tumor necrosis factor antagonist with anti-inflammatory effects. It is currently approved in the US for psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis and juvenile rheumatoid arthritis. Clinical trials have shown this agent to have an excellent safety profile and to be well tolerated by both adult and pediatric patients.
摘要
依那西普是一种具有抗炎作用的肿瘤坏死因子拮抗剂。它目前在美国被批准用于治疗银屑病、银屑病关节炎、强直性脊柱炎、类风湿关节炎和幼年类风湿关节炎。临床试验表明，该药物具有出色的安全性，成年和儿科患者对其耐受性良好。
Zotero 插件